Romni Owens, MD
Internal Medicine · Atlanta, GANPI 1427294966
Payments from drug & device makers
Across 320 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$854
- Amgen$497
- AstraZeneca$463
- AbbVie$455
- Amarin Pharma, Inc.$314
- Sanofi-aventis U.S. LLC$252
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,049100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $854 |
| Amgen | 31 | $497 |
| AstraZeneca | 28 | $463 |
| AbbVie(2 entities) | 28 | $455 |
| Amarin Pharma, Inc. | 20 | $314 |
| Sanofi-aventis U.S. LLC | 15 | $252 |
| Pfizer | 17 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $197 |
| Novartis | 8 | $169 |
| Astellas Pharma US Inc | 8 | $159 |
| Lilly USA, LLC | 9 | $145 |
| Johnson & Johnson | 9 | $130 |
| Boehringer Ingelheim | 6 | $110 |
| Abbott | 6 | $107 |
| Viiv Healthcare Company | 1 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $79 |
| Bayer | 4 | $64 |
| Exact Sciences | 3 | $59 |
| Merck | 5 | $58 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Ironwood Pharmaceuticals, Inc | 3 | $44 |
| Antares Pharma, Inc. | 2 | $44 |
| Eisai Inc. | 3 | $44 |
| Shield Therapeutics Inc | 2 | $42 |
| GSK | 3 | $40 |
| Esperion Therapeutics, Inc. | 3 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $36 |
| Radius Health, Inc. | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Aytu Biopharma, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $16 |
| BD | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$5,055 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $89,050 |
| MounjaroTirzepatide | 17 | $29,330 |
| TradjentaLinagliptin | 18 | $25,615 |
| JanuviaSitagliptin Phosphate | 18 | $24,637 |
| RybelsusSemaglutide | 12 | $24,576 |
| EliquisApixaban | 27 | $24,203 |
| XareltoRivaroxaban | 18 | $22,365 |
| FarxigaDapagliflozin Propanediol | 24 | $18,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,599 |
| Spiriva RespimatTiotropium Bromide | 14 | $11,363 |
| LinzessLinaclotide | 18 | $10,588 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $5,648 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $4,594 |
| Duloxetine Hcl | 57 | $3,101 |
| Novolog FlexpenInsulin Aspart | 13 | $1,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $854 | $113,62677 claims |
| Boehringer IngelheimTradjenta, Spiriva Respimat | $110 | $36,97732 claims |
| Lilly USA, LLCMounjaro | $145 | $29,33017 claims |
| MerckJanuvia | $58 | $24,63718 claims |
| PfizerEliquis | $221 | $24,20327 claims |
| Johnson & JohnsonXarelto | $130 | $22,36518 claims |
| AstraZenecaFarxiga | $463 | $18,50524 claims |
| GSKTrelegy Ellipta | $40 | $12,59911 claims |
| AbbVieLinzess, Synthroid | $455 | $12,17330 claims |
| Sanofi-aventis U.S. LLCLantus | $252 | $88114 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $60443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Atlanta
- Kimball JohnsonAtlanta$51.1M
- Robert Springer IiiAtlanta$5.3M
- Paulina Rebolledo EsteinouAtlanta$2.1M
- Courtney SheltonAtlanta$1.2M
- Melanie ThompsonAtlanta$1.1M
- Tracey HenryAtlanta$305K
- David WatsonAtlanta$286K
- Priscilla Igho-PemuAtlanta$269K
- Robert HerreraAtlanta$261K
- Syed RahmanAtlanta$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.